PMID: 8608478Mar 1, 1996Paper

Identification of drug-resistant myeloid leukemic cells by measurement of DNA content, nuclear area, and detection of P-glycoprotein

Cancer
I EmuraT Chou

Abstract

This study was designed to evaluate the significance of aneuploidy in DNA ploidy, nuclear area, and expression of P-glycoprotein (P-GP) in differentiating drug-resistant myeloid leukemic cells (DRMLC) from drug-sensitive myeloid leukemic cells. Bone marrow aspirates from 28 myeloid leukemic patients were fixed in 95% ethanol solution and stained using the Papanicolaou method. The nuclear area and DNA content were measured. An immunohistochemical study was performed using monoclonal antibody (JSB-1) directed against P-GP. Leukemic cell morphology changed once or twice after the diagnosis of acute myeloid leukemia (AML), blastic crisis (BC) of chronic myeloid leukemia, or chronic neutrophilic leukemia. DRMLC showed severe atypia and were morphologically distinguishable from normal myeloblasts, promyelocytes, and drug-sensitive leukemic cells at the diagnosis of AML or BC. The mean nuclear index (NI) and DNA index (DI) of DRMLC were significantly larger than those of drug-sensitive leukemic cells of AML or BC. The frequency of aneuploidy and P-GP expression was 9.1% and 4.5%, respectively, at the diagnosis of AML or BC, and 92.8% and 28.5%, respectively, for resistant disease. The incidence of heterogeneity in DNA ploidy was 86.3%...Continue Reading

References

Jul 1, 1991·British Journal of Haematology·J M BennettC Sultan
Jul 1, 1990·British Journal of Haematology·H SatoA Gottlieb
May 15, 1991·Journal of the National Cancer Institute·R PirkerL Havelec
Sep 15, 1988·International Journal of Cancer. Journal International Du Cancer·R J ScheperJ Lankelma
Jan 1, 1987·Acta Haematologica·M J KeatingE J Freireich
Dec 1, 1987·Investigational New Drugs·D A VorobiofA P Terblanche
May 28, 1987·The New England Journal of Medicine·I Pastan, M Gottesman
Aug 1, 1985·European Journal of Cancer & Clinical Oncology·P S MitrouH Bartels
Jan 1, 1983·Histochemistry·S Hamada, S Fujita
Jan 1, 1984·American Journal of Hematology·G Cantin, J K Brennan
Jan 1, 1982·Medical and Pediatric Oncology·A P EarlyJ A McBride
Apr 1, 1994·Leukemia Research·K Nooter, P Sonneveld

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.